Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | ATP4A | P20648 | 2/20 | 0.42 |
| ▸ | ATP4B | P51164 | 2/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | CFTR | P13569 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4656700 | 0.98 | NPC1 (0.42) | NPC1GFERATP4AATP4BGRM1 | |
| SCHEMBL4656607 | 0.97 | NPC1 (0.42) | NPC1GFERATP4AATP4BGRM1 | |
| SCHEMBL4655554 | 0.92 | CYP3A4 (0.39) | NPC1ATP4AATP4BGRM1RAB9A | |
| SCHEMBL5423067 | 0.91 | NPC1 (0.41) | NPC1GFERATP4AATP4BGRM1 | |
| SCHEMBL5421308 | 0.91 | NPC1 (0.41) | NPC1GFERATP4AATP4BGRM1 | |
| SCHEMBL4715023 | 0.90 | NPC1 (0.43) | NPC1GFERATP4AATP4BGRM1 | |
| SCHEMBL5430460 | 0.89 | NPC1 (0.39) | NPC1ATP4AATP4BRAB9AKMT2A | |
| SCHEMBL4658007 | 0.89 | NPC1 (0.42) | NPC1GFERATP4AATP4BGRM1 | |
| SCHEMBL4655649 | 0.89 | NPC1 (0.42) | NPC1GFERATP4AATP4BGRM1 | |
| SCHEMBL5425982 | 0.89 | NPC1 (0.43) | NPC1GFERGRM1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2460800-A1 | Substituted aminothiazole derivatives with anti-HCV activity | Achillion Pharmaceuticals, Inc. (US) | 2012-06-06 | — | — | EP | claimed |
| EP-1996565-A2 | SUBSTITUTED AMINOTHIAZOLE DERIVATIVES WITH ANTI-HCV ACTIVITY | Achillion Pharmaceuticals, Inc. (US) | 2008-12-03 | — | — | EP | claimed |
| WO-2007103550-A2 | SUBSTITUTED AMINOTHIAZOLE DERIVATIVES WITH ANTI-HCV ACTIVITY | ACHILLION PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | WO | claimed |
| US-20070213301-A1 | Substituted Aminothiazole Derivatives With Anti-HCV Activity | ACHILLION PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | claimed |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230295147-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | ARYL THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295147-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | ARYL THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20210230153-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | ARYL THERAPEUTICS, INC. | 2021-07-29 | — | — | US | disclosed |
| WO-2021127301-A1 | 4-PHENYL-N-(PHENYL)THIAZOL-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS FOR THE TREATMENT OF E.G. ANGIOGENESIS IMPLICATED OR INFLAMMATORY DISORDERS | Ikena Oncology, Inc. (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-2460800-A1 | Substituted aminothiazole derivatives with anti-HCV activity | Achillion Pharmaceuticals, Inc. (US) | 2012-06-06 | — | — | EP | disclosed |
| US-20070213301-A1 | Substituted Aminothiazole Derivatives With Anti-HCV Activity | ACHILLION PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213301-A1 | Substituted Aminothiazole Derivatives With Anti-HCV Activity | ACHILLION PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213301-A1 | Substituted Aminothiazole Derivatives With Anti-HCV Activity | ACHILLION PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | AHR, ARNT, HCAR1 | NPC1 1552/4885GFER 449/4885ATP4A 2837/4885 |
| US-20230295147-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | AHR, ARNT, HCAR1 | NPC1 1552/4885GFER 449/4885ATP4A 2837/4885 |
| US-20070213301-A1 | Substituted Aminothiazole Derivatives With Anti-HCV Activity | EIF2AK2, BCAT1, IL4I1 | NPC1 1995/4885GFER 1257/4885ATP4A 2766/4885 |
| US-20210230153-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | AHR, ARNT, HCAR1 | NPC1 1552/4885GFER 449/4885ATP4A 2837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.